Minot DeBlois Advisors’s AstraZeneca AZN Stock Holding History

Minot DeBlois Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.3K	Sell	37 -1	-3%	-$193	0.01%	145
2025 Q4	$6.89K	Hold	38	–	–	0.01%	134
2025 Q3	$5.75K	Hold	38	–	–	0.01%	174
2025 Q2	$5.24K	Hold	38	–	–	0.01%	193
2025 Q1	$5.51K	Hold	38	–	–	0.01%	188
2024 Q4	$4.91K	Buy	+38	New	+$5.32K	﹤0.01%	247

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Minot DeBlois Advisors's AZN Position: Q1 2026 in Review

Minot DeBlois Advisors reduced its AstraZeneca (AZN) stake by 2.6% in Q1 2026, selling an estimated $193 and leaving 37 shares worth $7.3K. The position accounts for 0.01% of the portfolio, ranked #145.

Minot DeBlois Advisors first reported a position in AZN in Q4 2024 and has held it in 6 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Minot DeBlois Advisors held 37 shares of AstraZeneca worth $7.3K as of Q1 2026.
Minot DeBlois Advisors sold 1 AstraZeneca share in Q1 2026, an estimated $193.
AstraZeneca made up 0.01% of Minot DeBlois Advisors's portfolio in Q1 2026, its #145 holding.
Minot DeBlois Advisors first reported a position in AstraZeneca in Q4 2024 and has held it in 6 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Minot DeBlois Advisors's 13F filing for Q1 2026, filed 8 May 2026.